Strategic Pharma and Biotech Consultants with Diverse, Real-World Experience

During the COVID-19 crisis, it is essential for drug manufacturers to start considering short-term relief for distributor partners and HCP offices. Begin by asking these questions.

What pharma and biotech professionals need to know about the Drug Supply Chain Security Act and new track-and-trace regulations. Full article published on Pharmaceutical Executive.

While the norm is to view an audit as a stressful, time-consuming experience, audits can paint a picture not visible to the naked eye and are a valuable exercise to gauge the current health of a pharmaceutical patient support program.

Q&A on how traditional pharmaceutical distribution must be transformed to meet the challenges of revolutionary Cell and Gene Therapies.

Pharmaceutical Executive worked with Archbow’s distribution experts, Kevin Cast, Rob Besse, and Paul Furgal, to find out which trends we should be watching as we welcome 2020.

A well-organized Ad Board can provide a pharmaceutical manufacturer with numerous advantages over traditional, structured market-research. These 5 essentials will help your next Ad Board be a success.

In a Q&A, Rob Besse shares his thoughts on making the leap from his family’s business to consulting, what manufacturers need to know before commercialization planning, and industry trends worth watching.

When manufacturers are planning the launch of a Buy-and-Bill product, there are certain steps that are imperative to include in the launch strategy and development of support services.

Determining if your HUB should be insourced, outsourced, or a hybrid of those two options is a big decision. And finding the right answer can determine the future success of your patient access program.

Before establishing an Expanded Access Program, it’s vital for manufacturers to align internally around several crucial program decisions. These five are key.